The global sterile injectables Contract Development and Manufacturing Organization (CDMO) market was valued at approximately USD 4.25 billion in 2024 and is projected to reach USD 7.29 billion by 2030, with a compound annual growth rate (CAGR) of 9.61% from 2025 to 2030. This growth is primarily fueled by the increasing pipeline and approvals for injectable medications.Pharmaceutical companies are increasingly focused on developing injectable drugs due to their multiple advantages, including rapid onset of action, precise dosing, and improved patient adherence.
The rising demand for cellular and genetic therapies is further propelling market growth. As therapy pipelines expand, there is an escalating need for specialized manufacturing capabilities that contract manufacturing organizations (CMOs) offer. For example, as reported by the American Society of Gene & Cell Therapy (ASGCT), there are currently 3,866 therapies in development, ranging from preclinical phases to preregistration. Among these, 2,082 are classified as gene therapies, which include genetically modified cell therapies such as CAR T-cell therapies, accounting for 53% of all gene, cell, and RNA therapies. Additionally, 862 therapies represent nongenetically modified cell therapies, constituting 22% of the therapies under development. Therefore, a robust product pipeline and the increasing demand for advanced therapeutics are expected to uplift overall market demand.
Key Market Trends & Insights
North America holds the largest revenue share of 40.64% in the sterile injectables CDMO market as of 2024, driven by the establishment of contract manufacturing facilities, the rise in chronic illnesses, and advancements in biotechnology.
The Asia Pacific region is anticipated to experience the highest CAGR of 10.91% during the forecast period, benefiting from cost-effective services and supportive regulatory changes, particularly in India and China. FDA and EMA-approved R&D and manufacturing facilities in this area are expected to attract foreign investment.
In terms of molecule type, the large molecule segment accounted for 66.00% of the market’s revenue in 2024, driven by increased investments in large molecule therapeutics, a growing pipeline of injectables, and regulatory approvals of biosimilars.
Regarding services, the formulation development segment led the market with a revenue share of 39.04% in 2024. This includes small-volume parenteral formulations like vials and ampoules, as well as large-volume parenteral solutions such as glucose and sodium chloride solutions.
The oncology segment led in revenue with 29.67% in 2024, attributed to the rising incidence of cancer worldwide, which has increased the demand for effective oncology treatments and sterile injectables manufacturing services from CDMOs.
Order a free sample PDF of the Sterile Injectables CDMO Market Intelligence Study, published by Grand View Research.
Market Size & Forecast
2024 Market Size: USD 4.25 Billion
2030 Projected Market Size: USD 7.29 Billion
CAGR (2025-2030): 9.61%
North America: Largest market in 2024
Asia Pacific: Fastest growing market